Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) is now available.
AstraZeneca Pharma India Limited has disclosed that its registrar and transfer agent, Integrated Registry Management Services, has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for March 2026. The certification attests that shares sent for dematerialisation were properly processed, including listing alignment, cancellation of physical certificates and updating the depository as the registered owner, reinforcing the company’s adherence to securities handling and investor protection norms.
This regulatory confirmation supports the integrity of AstraZeneca Pharma India’s share dematerialisation process and strengthens confidence among investors and market participants. By demonstrating timely compliance with SEBI’s depository rules through an independent registrar, the company underlines its governance standards and operational discipline in securities administration within India’s capital markets.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development, manufacturing and marketing of prescription medicines in India. The company serves the domestic healthcare market with a portfolio typically spanning key therapeutic areas, aligning its operations with Indian regulatory and capital market frameworks.
Average Trading Volume: 448
Technical Sentiment Signal: Strong Buy
Current Market Cap: 214.4B INR
For detailed information about ASTRAZEN stock, go to TipRanks’ Stock Analysis page.